MCID: BNS007
MIFTS: 44

Bone Sarcoma

Categories: Bone diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Bone Sarcoma

MalaCards integrated aliases for Bone Sarcoma:

Name: Bone Sarcoma 59

Characteristics:

Orphanet epidemiological data:

59
bone sarcoma
Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe);

Classifications:

Orphanet: 59  
Rare bone diseases


External Ids:

UMLS via Orphanet 73 C0029463 C1704327
Orphanet 59 ORPHA223727

Summaries for Bone Sarcoma

MalaCards based summary : Bone Sarcoma is related to exanthem and mesenchymoma. An important gene associated with Bone Sarcoma is MTAP (Methylthioadenosine Phosphorylase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Miconazole and Dasatinib have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and t cells, and related phenotypes are cardiovascular system and hematopoietic system

Related Diseases for Bone Sarcoma

Diseases related to Bone Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 237)
# Related Disease Score Top Affiliating Genes
1 exanthem 30.2 IL6 IL1RN CTLA4
2 mesenchymoma 30.1 MB DES
3 hematopoietic stem cell transplantation 30.0 IL6 IL10 CTLA4
4 paracoccidioidomycosis 30.0 IL6 IL10 CTLA4
5 osteomyelitis 29.9 IL6 IL1RN IL10 CXCL8
6 bilateral retinoblastoma 29.9 MB DES
7 toxic shock syndrome 29.9 IL6 IL10 CXCL8
8 synovitis 29.7 IL6 IL1RN CXCL8
9 bone inflammation disease 29.4 IL6 IL1RN IL10 CXCL8
10 ewing sarcoma 29.1 IL6 DES CTLA4 CSF3 CCNB3 BCOR
11 kaposi sarcoma 28.9 SRC IL6 CXCL8
12 osteogenic sarcoma 11.7
13 diaphyseal medullary stenosis with malignant fibrous histiocytoma 11.3
14 li-fraumeni syndrome 11.1
15 li-fraumeni syndrome 2 11.1
16 sarcoma 10.8
17 spindle cell sarcoma 10.8
18 leukoregulin 10.6 CXCL8 CSF1
19 soft tissue sarcoma 10.6
20 chondrosarcoma 10.6
21 tungiasis 10.6 IL10 CXCL8
22 neurosyphilis 10.5 IL10 CXCL8
23 scabies 10.5 IL10 CXCL8
24 recurrent corneal erosion 10.5 IL6 CXCL8
25 vulvovaginitis 10.5 IL10 CXCL8
26 bagassosis 10.5 IL6 CXCL8
27 necatoriasis 10.5 IL10 CXCL8
28 giant cell myocarditis 10.5 MB DES
29 streptococcal toxic-shock syndrome 10.5 IL6 CXCL8
30 kidney sarcoma 10.5 MB BCOR
31 malignant triton tumor 10.4 MB DES
32 eye lymphoma 10.4 IL6 IL10
33 botryoid rhabdomyosarcoma 10.4 MB DES
34 vulvar vestibulitis syndrome 10.4 IL1RN IL1R1
35 engraftment syndrome 10.4 CXCL8 CSF3
36 anca-associated vasculitis 10.4 IL6 CTLA4
37 myofibroma 10.3 MB DES
38 pouchitis 10.3 IL1RN IL10 CXCL8
39 fasciitis 10.3 IL6 DES CXCL8
40 spindle cell rhabdomyosarcoma 10.3 MB DES
41 juvenile ankylosing spondylitis 10.3 IL6 IL1RN
42 meningitis 10.3 IL6 IL10 CXCL8
43 monocytic leukemia 10.3 IL6 CXCL8 CSF1
44 peptic ulcer disease 10.3 IL1RN IL10 CXCL8
45 periodontitis 10.3 IL6 IL10 CXCL8
46 acute transverse myelitis 10.3 IL6 IL10 CXCL8
47 uveitis 10.3 IL1R1 IL10 CTLA4
48 transverse myelitis 10.3 IL6 IL10 CXCL8
49 funisitis 10.3 IL6 IL10 CXCL8
50 leiomyosarcoma 10.3

Graphical network of the top 20 diseases related to Bone Sarcoma:



Diseases related to Bone Sarcoma

Symptoms & Phenotypes for Bone Sarcoma

MGI Mouse Phenotypes related to Bone Sarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.22 BCOR CSF1 CTLA4 DES IL10 IL1R1
2 hematopoietic system MP:0005397 10.21 BCOR CSF1 CSF3 CTLA4 IL10 IL18R1
3 immune system MP:0005387 10.18 BCOR CSF1 CSF3 CTLA4 IL10 IL18R1
4 cellular MP:0005384 10.16 BCOR CSF1 DES IL10 IL1R1 IL1RN
5 mortality/aging MP:0010768 10.03 BCOR CSF1 CTLA4 DES IL10 IL1R1
6 integument MP:0010771 10.02 CSF1 CSF3 CTLA4 IL10 IL1R1 IL1RN
7 liver/biliary system MP:0005370 9.87 CSF1 CTLA4 IL10 IL1R1 IL6 MTAP
8 muscle MP:0005369 9.7 CSF1 DES IL10 IL1R1 IL6 MB
9 respiratory system MP:0005388 9.61 CSF1 CTLA4 IL10 IL1R1 IL6 MB
10 skeleton MP:0005390 9.23 CSF1 CTLA4 IL10 IL1R1 IL1RN IL6

Drugs & Therapeutics for Bone Sarcoma

Drugs for Bone Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 104)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
2
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
3
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
4
Vincristine Approved, Investigational Phase 2 57-22-7, 2068-78-2 5978
5
nivolumab Approved Phase 1, Phase 2 946414-94-4
6
Sunitinib Approved, Investigational Phase 1, Phase 2 557795-19-4, 341031-54-7 5329102
7
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
8
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
9
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
10
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
11
Pembrolizumab Approved Phase 2 1374853-91-4
12
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
13
Ifosfamide Approved Phase 2 3778-73-2 3690
14
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
15
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
16
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
17
leucovorin Approved Phase 2 58-05-9 143 6006
18
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
19
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
20
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
21
Lenograstim Approved, Investigational Phase 2 135968-09-1
22
Serine Approved, Nutraceutical Phase 2 56-45-1 5951
23
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 54670067 5785
24
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
25 Exatecan Investigational Phase 2 171335-80-1
26
Camptothecin Experimental Phase 2 7689-03-4
27
Emodepside Investigational, Vet_approved Phase 2 155030-63-0
28 Antihypertensive Agents Phase 2
29 Veratrum Alkaloids Phase 2
30 Antifungal Agents Phase 2
31 Antibodies, Monoclonal Phase 2
32 Imatinib Mesylate Phase 2 220127-57-1 123596
33 Antineoplastic Agents, Phytogenic Phase 2
34 Tubulin Modulators Phase 2
35 Cyclosporins Phase 2
36 Calcineurin Inhibitors Phase 2
37 Anti-Infective Agents Phase 2
38 Pharmaceutical Solutions Phase 1, Phase 2
39 Angiogenesis Inhibitors Phase 1, Phase 2
40 Angiogenesis Modulating Agents Phase 1, Phase 2
41 Analgesics Phase 2
42 Analgesics, Non-Narcotic Phase 2
43 Peripheral Nervous System Agents Phase 2
44 Vidarabine Phosphate Phase 2
45 Anti-HIV Agents Phase 2
46 Anti-Retroviral Agents Phase 2
47 Interleukin-2 Phase 2
48 Antibodies Phase 2
49 Antineoplastic Agents, Immunological Phase 2
50 Immunoglobulins Phase 2

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 PhaseⅡ Study of Weekly Docetaxel and Fixed-Dose Rate Gemcitabine in Patient With Previously Treated Advanced Soft Tissue and Bone Sarcoma Prospective, Open Label, Multi-Institutional Unknown status NCT00807261 Phase 2 Gemcitabine and Docetaxel
2 A Phase 2, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of IPI-926 in Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma Completed NCT01310816 Phase 2 IPI-926;Placebo Arm
3 A Phase 2 Study of Temsirolimus (CCI-779, NSC 683864) and IGF-1 Receptor Antibody Cixutumumab (IMC-A12, NSC 742460) in Patients With Metastatic Sarcomas Completed NCT01016015 Phase 2 Temsirolimus
4 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
5 A Phase II Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
6 Exatecan As Second-Line Treatment In Advanced Adult Soft Tissue Sarcoma: A Phase II - Study Of The EORTC Soft Tissue And Bone Sarcoma Group Completed NCT00041236 Phase 2 exatecan mesylate
7 Phase II Trial of Linsitinib (Anti-IGF-1R/IR) in Patients With Relapsed and/or Refractory Ewing Sarcoma Completed NCT02546544 Phase 2 Linsitinib
8 Exploratory Study of Non-Myeloablative Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusions for Metastatic Neoplasms Refractory to Standard Therapy Completed NCT00001880 Phase 2 methotrexate;cyclosporin
9 Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma Completed NCT00802880 Phase 2 Dacarbazine
10 A Phase II Study to Evaluate the Pharmacokinetics, Safety, and Obtain a Preliminary Efficacy Assessment of Palifermin in Patients With Sarcoma Receiving Multicycle Chemotherapy With Doxorubicin and Ifosfamide Completed NCT00267046 Phase 2 Palifermin;Placebo;Adriamycin (Doxorubicin);Ifosfamide;Vincristine;Cisplatin
11 Phase I-II Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas Recruiting NCT03277924 Phase 1, Phase 2 Sunitinib 37.5 MG [Sutent];Nivolumab 10 MG/ML [Opdivo]
12 Clinical Study to Assess Efficacy and Safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types Recruiting NCT03449108 Phase 2 Cyclophosphamide;Fludarabine;Fludarabine Phosphate
13 SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas Active, not recruiting NCT02301039 Phase 2 Pembrolizumab
14 Phase I/ II Study of Pulmonary Suffusion to Control Minimal Residual Disease in Resectable Sarcoma Pulmonary Metastases Not yet recruiting NCT03965234 Phase 1, Phase 2 Cisplatin
15 Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration Not yet recruiting NCT04040205 Phase 2 Abemaciclib
16 A Phase II Trial of Gemcitabine Plus High-Dose Ascorbate in Locally Advanced Unresectable or Metastatic Soft Tissue and Bone Sarcomas in Adults Suspended NCT03468075 Phase 2 Ascorbate;Gemcitabine
17 A Phase II Study of Sorafenib and Ifosfamide as a Treatment for Patients With Sarcoma Terminated NCT00880542 Phase 2 sorafenib;Ifosfamide
18 A Randomised, Cross-over Phase II Study to Investigate the Efficacy and Safety of Glucarpidase for Routine Use After High Dose Methotrexate in Patients With Bone Sarcoma Terminated NCT02022358 Phase 2 Glucarpidase;Methotrexate;Folinic Acid
19 Phase II Trial of Neoadjuvant Dose-Dense Doxorubicin, Ifosfamide, and Irinotecan (CPT-11) for Advanced Soft Tissue and Recurrent Bone Sarcomas Terminated NCT00544778 Phase 2 dexrazoxane hydrochloride;doxorubicin hydrochloride;ifosfamide;irinotecan hydrochloride
20 An Open-Label Phase IB Trial To Evaluate the Effects of Food and Formulation on Pharmacokinetics of the Oral Selective Inhibitor of Nuclear Export/SINE Compound KPT-330 in Patients With Soft-Tissue or Bone Sarcoma Completed NCT01896505 Phase 1 KCP-330
21 In Vivo Lung Perfusion (IVLP) as an Adjuvant Treatment for Patients Undergoing Surgical Resection of Pulmonary Metastases of Bone and Soft Tissues Sarcomas Recruiting NCT02811523 Phase 1 Doxorubicin
22 To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Bone and Soft Tissue Sarcoma Recruiting NCT03462316 Phase 1
23 A Phase I/II Open-label Study of Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia (CIT) in Subjects With Advanced Soft Tissue and Bone Sarcomas Receiving Gemcitabine and Docetaxel Chemotherapy Terminated NCT01491594 Phase 1 Eltrombopag
24 A Multi-center Phase I Trial of Temsirolimus in Combination With Valproic Acid in Children and Adolescents With Multiply Relapsed Pediatric Solid Tumors Terminated NCT01204450 Phase 1 Temsirolimus;Valproic Acid
25 Osteosarcoma and Ewing Sarcoma Treatment Response Assessment With Functional MRI Imaging in Children and Young Adults Unknown status NCT01780779
26 Neutrophil Extracellular Traps (NETs) Formation Following Chemotherapy for Pediatric Hematological and Solid Tumors, and Its Relation to Other Neutrophil Functions and the Role of NETs in Antitumor Activity Unknown status NCT01533779
27 Quantifying and Measuring the Economic Impact of Nursing Activities During the Hospital Stay of High Complexity Oncologic Care Patients Unknown status NCT02845583
28 Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment Completed NCT00824083
29 A European Treatment Protocol for Bone-sarcoma in Patients Older Than 40 Years Completed NCT02986503 Doxorubicin+cisplatin+ifosfamide;Doxorubicin+cisplatin+ifosfamide+methotrexate
30 Long Term Clinical and Functional Outcome in Patients Operated on Van Ness-Borggreve Rotationplasty for Lower Limnb Bone Tumor Completed NCT03385694
31 Dynamic Contrast Enhanced MRI(DCE-MRI)of Bone Tumors Completed NCT00598741
32 Clinical Evaluation for Sarcoma Originated From Bone Recruiting NCT03358992
33 Pre-Surgical Supervised Exercise for Bone Cancer Patients Recruiting NCT02893397
34 Transcultural Validation of MSTS and TESS Questionnaire Recruiting NCT03765970
35 Assessment of Healing and Function After Surgical Reconstruction for Osseous Sarcomas Recruiting NCT03442465
36 Etiosarc: Study of the Environmental Aetiology (Environment, Occupations and Lifestyle) of Sarcomas (Soft Tissue, Visceral and Bone) From a Multicenter French Population-based Case-control Study Among Adults. Recruiting NCT03670927
37 DVT Prophylaxis in Orthopaedic Oncology Patients - A Safety Study Active, not recruiting NCT00525057 Dalteparin
38 Prospective Evaluation of Abscopal Radiation Effects on Regional and Distant Bone Enrolling by invitation NCT03134742
39 A Randomized, Placebo-controlled, Double-blinded, Multicentre Study Evaluating the Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas Not yet recruiting NCT04055220 Treatment by Regorafenib;Treatment by Placebo

Search NIH Clinical Center for Bone Sarcoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Doxorubicin

Genetic Tests for Bone Sarcoma

Anatomical Context for Bone Sarcoma

MalaCards organs/tissues related to Bone Sarcoma:

41
Bone, Lung, T Cells, Breast, Brain, Neutrophil, Bone Marrow

Publications for Bone Sarcoma

Articles related to Bone Sarcoma:

(show top 50) (show all 770)
# Title Authors PMID Year
1
The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1. 38
31253399 2019
2
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations. 38
31434953 2019
3
Bone Sarcoma With EWSR1-NFATC2 Fusion: Sarcoma With Varied Morphology and Amplification of Fusion Gene Distinct From Ewing Sarcoma. 38
30714449 2019
4
Ion channels in sarcoma: pathophysiology and treatment options. 38
31377822 2019
5
[The importance of radiology in bone sarcoma diagnostics : Initial and advanced diagnostics]. 38
31392388 2019
6
Stanmore noninvasive extendible endoprosthesis in the treatment of bone sarcoma in the preadolescent. 38
31093984 2019
7
SFCE METRO-01 four-drug metronomic regimen phase II trial for pediatric extracranial tumor. 38
30920117 2019
8
Oncological and endoprosthetic outcomes of bone sarcoma patients: a nationwide cohort study. 38
31324968 2019
9
CORR Insights®: Can Navigation Improve the Ability to Achieve Tumor-free Margins in Pelvic and Sacral Primary Bone Sarcoma Resections? A Historically Controlled Study. 38
31135541 2019
10
CORR® Tumor Board: Can Navigation Improve the Ability to Achieve Tumor-free Margins in Pelvic and Sacral Primary Bone Sarcoma Resections? A Historically Controlled Study. 38
31169622 2019
11
Can Navigation Improve the Ability to Achieve Tumor-free Margins in Pelvic and Sacral Primary Bone Sarcoma Resections? A Historically Controlled Study. 38
31107331 2019
12
Assessment of resection margins in bone sarcoma treated by neoadjuvant chemotherapy: Literature review and guidelines of the bone group (GROUPOS) of the French sarcoma group and bone tumor study group (GSF-GETO/RESOS). 38
30962172 2019
13
Deep integrative analysis of microRNA-mRNA regulatory networks for biomarker and target discovery in chondrosarcoma. 38
30520120 2019
14
Bone sarcoma incidence in the Netherlands. 38
30903831 2019
15
Antiproliferative effect of the histone demethylase inhibitor GSK-J4 in chondrosarcomas. 38
31241814 2019
16
Resection margins obtained with patient-specific instruments for resecting primary pelvic bone sarcomas: A case-control study. 38
30982774 2019
17
Management of Sarcoma in Adolescents and Young Adults: An Australian Population-Based Study. 38
30822262 2019
18
Identifying bone sarcoma survivors facing psychosocial challenges. A study of trajectories following treatment. 38
31184795 2019
19
Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice. 38
30956944 2019
20
Current review of surgical management options for extremity bone sarcomas. 38
31191985 2019
21
Effective nutritional status screening in orthopaedic oncology patients and post-operative complications. 38
31084248 2019
22
Decision-making in Orthopaedic Oncology: Does Cognitive Bias Affect a Virtual Patient's Choice Between Limb Salvage and Amputation? 38
31173578 2019
23
Generation of patient-derived tumor xenografts from percutaneous tumor biopsies in children with bone sarcomas. 38
30548185 2019
24
Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group. 38
30602058 2019
25
Serum Biomarkers as Prognostic Factors for Metastatic Sarcoma. 38
30744933 2019
26
Advances in immune checkpoint inhibitors for bone sarcoma therapy. 38
30775238 2019
27
H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features. 38
30291346 2019
28
Chordoma: update on disease, epidemiology, biology and medical therapies. 38
30585858 2019
29
The impact of severe late-effects after 12 Gy fractionated total body irradiation and allogeneic stem cell transplantation for childhood leukemia (1988-2010). 38
30978121 2019
30
Adenoviral delivery of VHL suppresses bone sarcoma cell growth through inhibition of Wnt/β-catenin signaling. 38
30140042 2019
31
Real-World Experiences with Pazopanib in Patients with Advanced Soft Tissue and Bone Sarcoma in Northern California. 38
30889920 2019
32
Pediatric Soft Tissue and Bone Sarcomas in Tanzania: Epidemiology and Clinical Features. 38
30917068 2019
33
Adjuvant Biophysical Therapies in Osteosarcoma. 38
30871044 2019
34
Short Term Complications and Functional Results of Sarcoma Limb Salvage Surgeries. 38
31211194 2019
35
Does Patellar Tendon Repair With Gastrocnemius Flap Augmentation Effectively Restore Active Extension After Proximal Tibial Sarcoma Resection? 38
30461516 2019
36
Use of Vascularized Fibular Free Flap in the Reconstruction of the Femur in Pediatric and Adolescent Bone Sarcomas: Complications and Functional Outcome. 38
30121051 2019
37
New TNM classification (AJCC eighth edition) of bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group. 38
30423153 2019
38
Health professional perceptions of communicating with adolescents and young adults about bone cancer clinical trial participation. 38
29978324 2019
39
Clinical epidemiology and treatment outcomes of spindle cell non-osteogenic bone sarcomas - A nationwide population-based study. 38
30568874 2019
40
Synovial sarcoma of bone: Sarcoma typically of soft tissues presenting as a primary bone tumor. 38
30425775 2019
41
Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone. 38
30281149 2019
42
Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma. 38
30082492 2019
43
Acid microenvironment promotes cell survival of human bone sarcoma through the activation of cIAP proteins and NF-κB pathway. 38
31285947 2019
44
New Advances in the Study of Bone Tumors: A Lesson From the 3D Environment. 38
31316395 2019
45
HACE1 is a potential tumor suppressor in osteosarcoma. 38
30622235 2019
46
The Heterogeneity of Osteosarcoma: The Role Played by Cancer Stem Cells. 38
31134502 2019
47
Growing Without Pain: The Noninvasive Expandable Prosthesis is Boon for Children with Bone Cancer, as well as Their Surgeons! 38
30905999 2019
48
Bone sarcoma during pregnancy: an example of personalized multidisciplinary care. 38
30264644 2019
49
The clinical outcomes of total femur prosthesis in patients with musculoskeletal tumors. 38
31250806 2019
50
Murine Models of Bone Sarcomas. 38
30729474 2019

Variations for Bone Sarcoma

Expression for Bone Sarcoma

Search GEO for disease gene expression data for Bone Sarcoma.

Pathways for Bone Sarcoma

Pathways related to Bone Sarcoma according to GeneCards Suite gene sharing:

(show all 46)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 TNFRSF1A SRC IL6 IL1RN IL1R1 IL18R1
2
Show member pathways
13.76 TNFRSF1A SRC IL6 IL1R1 IL18R1 IL10
3
Show member pathways
13.52 TNFRSF1A SRC IL6 IL1RN IL1R1 IL18R1
4
Show member pathways
13.48 TNFRSF1A SRC IL6 IL1R1 IL18R1 IL10
5
Show member pathways
13.23 TNFRSF1A SRC IL6 IL1R1 IL18R1 IL10
6
Show member pathways
13.09 TNFRSF1A SRC IL6 IL1R1 IL18R1 IL10
7
Show member pathways
12.96 TNFRSF1A SRC IL6 IL1RN IL1R1 IL18R1
8
Show member pathways
12.9 TNFRSF1A SRC IL6 IL1R1 CXCL8 CCNB3
9
Show member pathways
12.8 TNFRSF1A IL6 IL18R1 IL10 CXCL8 CTLA4
10
Show member pathways
12.53 IL6 IL1R1 IL18R1 IL10
11
Show member pathways
12.52 SRC IL6 IL18R1 IL10
12 12.49 TNFRSF1A IL1RN IL10 CTLA4
13
Show member pathways
12.33 SRC IL6 IL10 CSF3
14 12.18 TNFRSF1A SRC IL6 IL10
15 12.11 IL6 IL1RN IL10 CXCL8
16 12.02 TNFRSF1A SRC IL1R1 GSTA1
17 11.98 TNFRSF1A IL1R1 CSF1
18
Show member pathways
11.98 IL6 IL1R1 IL18R1 IL10
19 11.94 IL6 IL1R1 CXCL8
20 11.91 IL6 IL10 CXCL8
21 11.91 IL6 IL10 CSF3 CSF1
22 11.89 TNFRSF1A IL6 IL18R1 CSF1
23 11.87 SRC IL6 CXCL8
24 11.85 TNFRSF1A IL1R1 CXCL8
25 11.82 IL6 IL1R1 IL10 CXCL8
26 11.81 SRC IL6 IL10
27 11.81 IL6 IL1R1 CSF3 CSF1
28
Show member pathways
11.81 TNFRSF1A SRC IL6 IL1R1 IL18R1 IL10
29
Show member pathways
11.8 IL6 CXCL8 CSF3
30 11.76 IL6 CXCL8 CTLA4 CSF1
31 11.71 IL6 IL10 CXCL8
32 11.7 IL6 IL10 CSF1
33
Show member pathways
11.68 SRC IL6 IL1RN IL1R1 IL18R1 CXCL8
34 11.67 IL6 IL1RN IL10
35 11.63 SRC IL6 CXCL8
36
Show member pathways
11.61 TNFRSF1A IL6 CXCL8
37 11.61 IL6 CXCL8 CSF3
38 11.47 IL6 CSF3 CSF1
39 11.45 SRC IL6 CXCL8
40 11.4 IL6 IL10 CXCL8 CSF3
41 11.09 IL6 IL10 CXCL8 CSF3 CSF1
42 11.09 IL6 IL10 CSF3 CSF1
43 10.97 IL6 CXCL8
44 10.94 IL6 IL10 DES CXCL8 CSF3 CSF1
45 10.92 TNFRSF1A IL6 IL1RN IL1R1 IL10 CXCL8
46 10.91 SRC CXCL8

GO Terms for Bone Sarcoma

Cellular components related to Bone Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.23 TNFRSF1A IL6 IL1RN IL1R1 IL10 CXCL8

Biological processes related to Bone Sarcoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.76 IL6 IL1RN IL1R1 IL18R1 IL10 CXCL8
2 cellular response to lipopolysaccharide GO:0071222 9.73 SRC IL6 IL1RN IL10 CXCL8 CSF3
3 positive regulation of DNA-binding transcription factor activity GO:0051091 9.71 IL6 IL10 CSF3
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.65 SRC IL6 CSF3
5 response to glucocorticoid GO:0051384 9.61 IL6 IL1RN IL10
6 inflammatory response GO:0006954 9.56 TNFRSF1A IL6 IL1RN IL1R1 IL18R1 IL10
7 negative regulation of B cell proliferation GO:0030889 9.52 IL10 CTLA4
8 branching involved in mammary gland duct morphogenesis GO:0060444 9.51 SRC CSF1
9 response to molecule of bacterial origin GO:0002237 9.49 IL10 CXCL8
10 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.46 IL1RN IL10
11 positive regulation of T-helper 1 cell cytokine production GO:2000556 9.4 IL1R1 IL18R1
12 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.37 IL6 IL1RN
13 response to interleukin-1 GO:0070555 9.32 SRC IL1R1
14 cytokine-mediated signaling pathway GO:0019221 9.23 TNFRSF1A IL6 IL1RN IL1R1 IL10 CXCL8

Molecular functions related to Bone Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 IL6 IL10 CSF3 CSF1
2 interleukin-1 receptor activity GO:0004908 9.16 IL1R1 IL18R1
3 cytokine activity GO:0005125 9.1 IL6 IL1RN IL10 CXCL8 CSF3 CSF1

Sources for Bone Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....